Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arimoclomol in adults with sporadic inclusion body myositis
2008-008208-42Phase 2Completed
- Sponsor
- UCLH
- Start
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in sporadic inclusion body myositis (sIBM) and inclusion body myositis (IBM) comparing Arimoclomol with Placebo (2 arms). Primary endpoint: Adverse event reporting. Started May 2009; status: completed.
02
Drugs
arimoclomol
03
Conditions
sporadic inclusion body myositis (sIBM)inclusion body myositis (IBM)
Beyond the preview
Go deeper on 2008-008208-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008208-42.